Tag Archives: DCPH

Barclays Sticks to Their Buy Rating for Deciphera Pharmaceuticals (DCPH)

Barclays analyst Peter Lawson maintained a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report) yesterday and set a price target of $85.00. The company’s shares closed last Friday at $51.74. According to TipRanks.com, Lawson is a 5-star analyst with

Leerink Partners Keeps Their Hold Rating on Deciphera Pharmaceuticals (DCPH)

In a report released today, Andrew Berens from Leerink Partners maintained a Hold rating on Deciphera Pharmaceuticals (DCPH – Research Report), with a price target of $55.00. The company’s shares closed last Tuesday at $56.20. According to TipRanks.com, Berens is

JonesTrading Keeps a Buy Rating on Deciphera Pharmaceuticals (DCPH)

JonesTrading analyst Soumit Roy reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report) today. The company’s shares closed last Monday at $49.99. According to TipRanks.com, Roy is a 4-star analyst with an average return of 10.4% and a

Deciphera Pharmaceuticals (DCPH) Received its Third Buy in a Row

After JMP Securities and Guggenheim gave Deciphera Pharmaceuticals (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Deciphera Pharmaceuticals today and set a price

Deciphera Pharmaceuticals Inc (DCPH) Has a New Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on Deciphera Pharmaceuticals Inc (DCPH – Research Report) today and set a price target of $60.00. The company’s shares closed last Monday at $34.15. According to TipRanks.com, Fein ‘s

Deciphera Pharmaceuticals Inc (DCPH) Received its Third Buy in a Row

After Deutsche Bank and J.P. Morgan gave Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from Nomura. Analyst Christopher Marai maintained a Buy rating on Deciphera Pharmaceuticals Inc yesterday and set